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Immunosuppressive eff  ect of stromal cells
Multipotent mesenchymal stromal cells or mesenchymal 
stem cells (MSCs) are adult progenitor cells essentially 
isolated from bone marrow and adipose tissue and 
probably present in most of adult tissue, including 
muscle, synovial tissue, placental tissue, and recently the 
teeth [1]. Th   ey are currently under investigation for tissue 
engineering applications, in particular bone and cartilage 
repair, thanks to their potential to diﬀ  erentiate  into 
various lineages such as chondrocytes, osteoblasts, or 
adipocytes [2,3]. Th   ey may also have a therapeutic value 
in other clinical applications based on their capacity to 
limit scar formation through anti-ﬁ  brotic properties, to 
prevent apoptosis, to stimulate endogenous cells for 
regeneration, and to suppress the host immune response 
[4]. Such an immunosuppressive eﬀ  ect has been shown 
to occur mainly through the secretion of soluble factors 
by MSCs. Among the possible mediators identiﬁ  ed, 
indoleamine 2,3-dioxygenase (IDO), inducible nitric 
oxide synthase, and heme oxygenase-1 as well as the 
secretion of human leukocyte antigen G, transforming 
growth factor-beta, interleukin (IL)-6 or prostaglandin E2
have been postulated to play a role, but the cells need to 
be licensed through interferon-gamma [5,6]. Th  ese 
mecha  nisms result in the inhibition of the proliferation of 
CD4+ and CD8+ T cells, B lymphocytes, and natural killer 
cells that have been shown mainly in vitro but also in vivo
in a number of experimental models. MSCs have also 
been shown to induce in vivo regulatory T (Treg) cells 
through release of sHLAG5 and it has been shown that 
these foxP3 cells were functional. All of these biological 
eﬀ   ects are probably shared by all stromal cells, and 
similar dates have been shown with ﬁ  broblast  (CJ, 
unpublished data). In the previous issue of Stem Cell 
Research & Th  erapy, Yamaza and colleagues [1] demon-
strate similar immunomodulatory activities of stem cells 
from human exfoliated deciduous teeth.
What is the role of mesenchymal stromal cells in 
physiology?
MSCs in the bone marrow are in close contact with T 
and B cells. MSCs regulate immunological memory by 
organizing deﬁ  ned numbers of dedicated survival niches 
for plasma cells and memory T cells in the bone marrow. 
A distinct subpopulation of MSCs is characterized by the 
expression of CXCL12 and vCAM1. A distinct population 
of MSCs that express platelet-derived growth factor 
receptor-alpha with distinct properties is also described. 
Th  eir high expression of CXCL12 and their develop-
mental stability suggest that they might be the MSCs that 
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© 2010 BioMed Central Ltdprovide a survival niche for memory plasma cells [7]. In 
contrast, another fraction of CXCL12− vCAM1+ bone 
marrow MSCs expresses IL-7. Th  ese cells are in close 
contact with memory CD4+ T cells and keep the T cells 
quiescent through the eﬀ  ect of IL-7 [8]. Th  ese results 
suggest heterogeneity of MSCs in terms of immune and 
hematopoietic functions but also suggest that MSCs have 
a key role to maintain immune homeostasis.
Applications to immune diseases
Th  e immunosuppressive capacities of MSCs have been 
evaluated in experimental autoimmune models, as well as 
in humans, to prevent acute graft-versus-host disease [9]. 
Zappia and colleagues [10] were among the ﬁ  rst to report 
the therapeutic eﬃ     cacy of MSCs in the experimental 
autoimmune encephalomyelitis murine model of multiple 
sclerosis. In this model, MSCs decreased the clinical 
signs associated with demyelinization when injected 
before or at disease onset. No therapeutic eﬀ  ect  was 
observed when the injection occurred after disease 
stabili zation.  Th   e same results were observed in a model 
of autoimmune diabetes, in which MSC injection 
induced a decrease in mesangial thickening and in 
macro phage  inﬁ  ltration, resulting in the prevention of 
pancreatic injury. In the experimental collagen-induced 
arthritis (CIA) model, diﬀ   erent studies have shown 
contrasted results on the role of MSCs. Th  e  ﬁ  rst study on 
the use of MSCs in CIA showed that the allogeneic 
C3H10T1/2 cells did not exert a beneﬁ  cial eﬀ  ect on CIA 
[4]. Since then, it has been reported that a single injection 
of primary MSCs prevented the occurrence of severe 
arthritis and was associated with a decrease in serum 
pro-inﬂ  ammatory cytokines and an increase in Treg cells 
[11]. Similar results have been obtained in vitro and in 
vivo with human adipose-derived stem cells that were 
shown to suppress T-cell response through the 
generation/activation of antigen-speciﬁ  c Treg cells. Th  e 
role of MSCs in the immune-pathogeny of autoimmune 
diseases and the therapeutical perspective are expected 
in the near future, but the optimal source of stromal cells 
remains to be deﬁ  ned.
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